Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1F | O60840 | 4/20 | 0.51 |
| ▸ | CACNA1D | Q01668 | 4/20 | 0.51 |
| ▸ | CACNA1S | Q13698 | 4/20 | 0.51 |
| ▸ | CACNA1C | Q13936 | 4/20 | 0.51 |
| ▸ | ACHE | P22303 | 2/20 | 0.51 |
| ▸ | CACNB4 | O00305 | 2/20 | 0.51 |
| ▸ | CACNA1A | O00555 | 2/20 | 0.51 |
| ▸ | CACNA1G | O43497 | 2/20 | 0.51 |
| ▸ | CACNG3 | O60359 | 2/20 | 0.51 |
| ▸ | CACNA1H | O95180 | 2/20 | 0.51 |
| ▸ | CACNB3 | P54284 | 2/20 | 0.51 |
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.51 |
| ▸ | CACNG7 | P62955 | 2/20 | 0.51 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.51 |
| ▸ | CACNB1 | Q02641 | 2/20 | 0.51 |
| ▸ | CACNG1 | Q06432 | 2/20 | 0.51 |
| ▸ | CACNB2 | Q08289 | 2/20 | 0.51 |
| ▸ | CACNA1E | Q15878 | 2/20 | 0.51 |
| ▸ | CACNA2D4 | Q7Z3S7 | 2/20 | 0.51 |
| ▸ | CACNA2D3 | Q8IZS8 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5037185 | 0.87 | ALDH1A1 (0.40) | CACNA1FCACNA1DCACNA1SCACNA1CACHE | |
| SCHEMBL5037184 | 0.87 | ALDH1A1 (0.40) | CACNA1FCACNA1DCACNA1SCACNA1CACHE | |
| SCHEMBL4421035 | 0.82 | ACHE (0.49) | CACNA1FCACNA1DCACNA1SCACNA1CACHE | |
| SCHEMBL4426414 | 0.80 | LHCGR (0.57) | CACNA1FCACNA1DCACNA1SCACNA1CACHE | |
| SCHEMBL4426372 | 0.74 | MAPT (0.45) | CACNA1FCACNA1DCACNA1SCACNA1CACHE | |
| SCHEMBL4425667 | 0.74 | SLC6A2 (0.49) | CACNA1FCACNA1DCACNA1SCACNA1CACHE | |
| Hydrochloric Acid SCHEMBL10376597 | 0.70 | MAPT (0.55) | CACNA1FCACNA1DCACNA1SCACNA1CACHE | |
| SCHEMBL10915430 | 0.70 | ALDH1A1 (0.46) | MAPTALDH1A1MEN1KMT2APDE4B | |
| SCHEMBL14285233 | 0.70 | LHCGR (0.56) | MAPTALDH1A1MEN1KMT2ARAB9A | |
| SCHEMBL4906981 | 0.70 | LHCGR (0.56) | PDE4BPDE4DPDE4APDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7618963-B2 | Bicyclic heteroaromatic compounds | N.V. ORGANON (NL) | 2009-11-17 | — | — | US | disclosed |
| US-20070197527-A1 | Bicyclic heteroaromatic compounds | N.V. ORGANON (NL) | 2007-08-23 | — | — | US | disclosed |
| US-7229990-B2 | Bicyclic heteroaromatic compounds | N.V. ORGANON (NL) | 2007-06-12 | — | — | US | disclosed |
| CN-1247594-C | Bicyclic heteroaromatic compounds | OKZO NOBEL N V (NL) | 2006-03-29 | — | — | CN | disclosed |
| CN-1462273-A | Bicyclic heteroaromatic compounds | OKZO NOBEL N V (NL) | 2003-12-17 | — | — | CN | disclosed |
| US-20030225113-A1 | Bicyclic heteroaromatic compounds | MERCK SHARP & DOHME B.V. (NL) | 2003-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225113-A1 | Bicyclic heteroaromatic compounds | NR5A1, CYP19A1, FSHR | CACNA1F 1157/4885CACNA1D 1100/4885CACNA1S 879/4885 |
| US-20070197527-A1 | Bicyclic heteroaromatic compounds | NR5A1, CYP19A1, FSHR | CACNA1F 1039/4885CACNA1D 895/4885CACNA1S 699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.